Clinical Trial Update: Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the safety and efficacy of Cilostazol for nonalcoholic fatty liver disease has been withdrawn, covering Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• Cilostazol (Cilostazol)

Snippet

Sponsor: Sadat City University | Conditions: Fatty Liver, Nonalcoholic | Phase 1, Phase 2 | Status: WITHDRAWN